GlassScriptPhysician profile
Oskar Kigelman
NPI 1962995365
$808.84
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.88 · 2022: $332 · 2023: $268 · 2024: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $111.02 | 2022-2024 | Xpovio |
| Morphosys, US INC. | $67.78 | 2022-2024 | Monjuvi |
| Genzyme Corporation | $60.39 | 2022-2023 | |
| Exelixis INC. | $50.31 | 2021-2023 | Cabometyx |
| Glaxosmithkline, LLC. | $49.52 | 2022 | |
| Celgene Corporation | $46.67 | 2022 | |
| Alexion Pharmaceuticals, INC. | $45.84 | 2022-2023 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $43.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.22 | 2023-2024 | |
| Cti Biopharma Corp. | $34.39 | 2022-2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $27.15 | 2023 | Epkinly |
| Mirati Therapeutics, INC. | $26.71 | 2024 | Krazati |
| Tersera Therapeutics LLC | $26.19 | 2023 | Xermelo |
| Gilead Sciences, INC. | $25.76 | 2023 | |
| Abbvie INC. | $23.27 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $22.81 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.56 | 2022 | |
| Recordati_rare_diseases_inc. | $22.38 | 2024 | Sylvant |
| Daiichi Sankyo INC. | $21.16 | 2024 | Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Incyte Corporation | $18.46 | 2023 | Jakafi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oskar Kigelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.